What is Aztreonam?

Aztreonam is an antibiotic developed by Gilead that is currently in Stage 3 clinical trials. Stage 3 is the last step before the product becomes available to patients. Aztreonam is a beta-lactam, which means it is in the same family of antibiotics as meropenem.

This medication represents a very exciting new treatment against P. Aeruginosa infection. Study data in the United States has demonstrated the drug to be 88% effective against P. Aeruginosa (PA.) This is true not only in preventing PA infection in young patients, but in treating older patients who have been colonized with PA. Aztreonam is also showing a certain amount of effectiveness against certain strains of B. Cepacia.

Studies also show that Aztreonam is similar in effectiveness to ceftazadime for the treatment of pulmonary exacerbations. The drug will be available as an inhaled form to be used in the eFlow.

For more information about Aztreonam and press releases from Gilead Pharma, please see the following links:

Gilead Announces Detailed Results of Phase III Study of Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis

Gilead Submits New Drug Application to Use Aztreonam Lysine for Inhalation for CF

Other Press Releases